This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Eravacycline parenteral

Updated 2 Feb 2023 | Tetracyclines


Infusions of eravacycline.

Drugs List

  • eravacycline 100mg powder for solution for infusion vial
  • XERAVA 100mg powder for concentrate for soln for infusion vial
  • Therapeutic Indications


    Complicated intra-abdominal infections: treatment



    1mg/kg every 12 hours for 4 to 14 days.

    Additional Dosage Information

    Concomitant use of strong CYP3A4 inducers
    1.5mg/kg every 12 hours for 4 to 14 days.


    For intravenous infusion only over approximately 1 hour.


    Children under 18 years

    Precautions and Warnings

    Females of childbearing potential
    Severe hepatic impairment

    Advise ability to drive/operate machinery may be affected by side effects
    Consult national/regional policy on the use of anti-infectives
    Suspend treatment or reduce rate until infusion reactions resolve
    Exclude pregnancy prior to initiation of treatment
    Consider pseudomembranous colitis if patient presents with diarrhoea
    May cause tooth discolouration during tooth development
    Prolonged use may result in superinfection with non-susceptible organisms
    Advise patient to seek advice at first indications of pregnancy
    Discontinue at once if pseudomembranous colitis occurs
    Discontinue if pancreatitis is suspected
    Discontinue if severe hypersensitivity reactions occur
    Advise patient not to take St John's wort concurrently

    Patients with severe hepatic impairment should be monitored for adverse reactions, particularly if the patient is obese and/or being treated with strong CYP3A inhibitors where the exposure may further increased.

    Pregnancy and Lactation


    Eravacycline is contraindicated during pregnancy.

    The manufacturer advises that eravacycline should not be used during pregnancy unless the clinical condition of the women requires treatment with eravacycline.

    At the time of writing there are limited data on the use of eravacycline in pregnant women. Animal studies have shown reproductive toxicity. The potential risk to humans is unknown. Eravacycline may induce permanent dental defects (discolouration and enamel defects) and a delay in ossification processes in fetuses exposed in utero during 2nd and 3rd trimester, due to accumulation in tissues with a high calcium turnover and formation of calcium chelate complexes.


    Eravacycline is contraindicated during breastfeeding.

    The manufacturer advises that a decision on whether to discontinue breastfeeding or to discontinue therapy with eravacycline should be made, taking into account the benefit of breastfeeding for the child, and the benefit of therapy for the woman.

    It is unknown whether eravacycline and its metabolites are excreted in human breast milk. Animal studies have shown excretion of eravacycline and its metabolites in breast milk. Long term use of other tetracyclines during breastfeeding may result in significant absorption by the breastfed infant and is not recommended because of the risk of dental discolouration and delay ossification.

    Side Effects

    Alanine aminotransferase increased
    Antibiotic-associated colitis
    Aspartate aminotransferase increased
    Dental discolouration
    Erythema at injection site
    Fungal superinfection
    Hypersensitivity reactions
    Hypoaesthesia (injection site)
    Increase in blood urea nitrogen
    Inflammation (injection site)
    Infusion site pain
    Infusion site reaction
    Pain / soreness (injection site)
    Pseudomembranous colitis
    Pseudotumor cerebri
    Swelling (injection site)
    Thrombosis (injection site)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2022

    Reference Sources

    Summary of Product Characteristics: Xerava 100mg powder for concentrate for solution for infusion. PAION UK Ltd. Revised August 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.